MX343505B - Metodos y composiciones para inhibir la transmision del vih. - Google Patents
Metodos y composiciones para inhibir la transmision del vih.Info
- Publication number
- MX343505B MX343505B MX2012011574A MX2012011574A MX343505B MX 343505 B MX343505 B MX 343505B MX 2012011574 A MX2012011574 A MX 2012011574A MX 2012011574 A MX2012011574 A MX 2012011574A MX 343505 B MX343505 B MX 343505B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- inhibiting hiv
- hiv transmission
- transmission
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000005540 biological transmission Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un método no terapéutico para producir anticuerpos policlonales capaces de unirse a una proteína de la envoltura viral (Env) de una cepa heterologa del virus de la inmunodeficiencia humana a (VIH), el método se caracteriza porque comprende: inmunizar un animal hembra no humano antes o durante un embarazo con una dosis primaria de una proteína de la envoltura (Env) del virus de la inmunodeficiencia humana (VIH) de suptipo B gp140 oligomérica o un fragmento de la misma, inmunizar el animal hembra no humano durante el embarazo con tres o más dosis de refuerzo de una proteína Env del VIH de suptipo B gp 140 oligomérica o un fragmento de la misma, y obtener lecho o colostro del animal no humano. Figura. 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32239910P | 2010-04-09 | 2010-04-09 | |
| PCT/AU2011/000407 WO2011123900A1 (en) | 2010-04-09 | 2011-04-11 | Methods and compositions for inhibiting hiv transmission |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012011574A MX2012011574A (es) | 2013-03-05 |
| MX343505B true MX343505B (es) | 2016-11-04 |
Family
ID=44761932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012011574A MX343505B (es) | 2010-04-09 | 2011-04-11 | Metodos y composiciones para inhibir la transmision del vih. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130022619A1 (es) |
| EP (1) | EP2555798B1 (es) |
| JP (1) | JP6026402B2 (es) |
| CN (1) | CN103167881B (es) |
| AP (1) | AP3469A (es) |
| AU (2) | AU2011238431B2 (es) |
| BR (1) | BR112012025678A2 (es) |
| CA (1) | CA2795853A1 (es) |
| MX (1) | MX343505B (es) |
| RU (1) | RU2594249C2 (es) |
| WO (1) | WO2011123900A1 (es) |
| ZA (1) | ZA201207790B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3049524A4 (en) * | 2013-09-27 | 2017-06-14 | Duke University | Hiv-1 mother-to-child transmission correlates of protection and vaccine |
| CN103736100B (zh) * | 2013-12-25 | 2017-06-09 | 南方医科大学 | 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体 |
| EP3662930A1 (en) * | 2015-09-24 | 2020-06-10 | AbVitro LLC | Hiv antibody compositions and methods of use |
| WO2017062070A1 (en) * | 2015-10-07 | 2017-04-13 | Eca Medical Instruments | Gearless compact torque drive |
| US10973679B2 (en) * | 2016-02-12 | 2021-04-13 | Adam Arreola | STD detecting condom |
| CN116171165A (zh) * | 2020-06-10 | 2023-05-26 | 墨尔本大学 | Hiv-1抗体 |
| IL308087A (en) | 2021-05-12 | 2023-12-01 | Applied Biomedical Science Inst | Methods for the screening and expression of disulfide-bonded polypeptides |
| WO2022241057A1 (en) | 2021-05-12 | 2022-11-17 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
| JP7421610B1 (ja) | 2022-08-18 | 2024-01-24 | 株式会社マーベラス | ゲーム装置 |
| WO2024108050A1 (en) | 2022-11-16 | 2024-05-23 | Applied Biomedical Science Institute | Fusion polypeptides and binding peptides and methods for producing and using same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6039957A (en) * | 1993-12-10 | 2000-03-21 | United States Of America, As Represented By The Department Of Health And Human Services | Oligomeric HIV-1 envelope glycoproteins |
| AU777241B2 (en) * | 1999-06-24 | 2004-10-07 | Johns Hopkins University, The | Compositions and methods for preventing transepithelial transmission of HIV |
| US6753015B2 (en) * | 2000-09-28 | 2004-06-22 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
| WO2008063331A2 (en) * | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| CA2704059A1 (en) * | 2007-10-30 | 2009-05-07 | International Aids Vaccine Initiative | Antigen-antibody complexes as hiv-1 vaccines |
| CA2739905A1 (en) * | 2008-10-30 | 2010-08-26 | Dana-Farber Cancer Institute | Mimotopes of hiv env |
-
2011
- 2011-04-11 CN CN201180028300.5A patent/CN103167881B/zh not_active Expired - Fee Related
- 2011-04-11 MX MX2012011574A patent/MX343505B/es active IP Right Grant
- 2011-04-11 AU AU2011238431A patent/AU2011238431B2/en not_active Ceased
- 2011-04-11 US US13/639,831 patent/US20130022619A1/en not_active Abandoned
- 2011-04-11 WO PCT/AU2011/000407 patent/WO2011123900A1/en active Application Filing
- 2011-04-11 AP AP2012006519A patent/AP3469A/xx active
- 2011-04-11 EP EP11764957.4A patent/EP2555798B1/en not_active Not-in-force
- 2011-04-11 RU RU2012142999/15A patent/RU2594249C2/ru not_active IP Right Cessation
- 2011-04-11 JP JP2013502959A patent/JP6026402B2/ja not_active Expired - Fee Related
- 2011-04-11 BR BR112012025678A patent/BR112012025678A2/pt not_active Application Discontinuation
- 2011-04-11 CA CA2795853A patent/CA2795853A1/en not_active Abandoned
-
2012
- 2012-10-17 ZA ZA2012/07790A patent/ZA201207790B/en unknown
-
2017
- 2017-11-22 AU AU2017265055A patent/AU2017265055A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103167881A (zh) | 2013-06-19 |
| RU2594249C2 (ru) | 2016-08-10 |
| AP3469A (en) | 2015-11-30 |
| EP2555798A1 (en) | 2013-02-13 |
| EP2555798A4 (en) | 2013-11-20 |
| MX2012011574A (es) | 2013-03-05 |
| CA2795853A1 (en) | 2011-10-13 |
| AU2011238431A1 (en) | 2012-11-08 |
| RU2012142999A (ru) | 2014-05-20 |
| CN103167881B (zh) | 2017-06-16 |
| JP2013523783A (ja) | 2013-06-17 |
| EP2555798B1 (en) | 2016-06-22 |
| AP2012006519A0 (en) | 2012-10-31 |
| ZA201207790B (en) | 2013-06-26 |
| AU2011238431B2 (en) | 2016-10-06 |
| JP6026402B2 (ja) | 2016-11-16 |
| US20130022619A1 (en) | 2013-01-24 |
| WO2011123900A1 (en) | 2011-10-13 |
| AU2017265055A1 (en) | 2019-06-06 |
| BR112012025678A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502489A1 (en) | Antiviral therapy | |
| MX343505B (es) | Metodos y composiciones para inhibir la transmision del vih. | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| MY169159A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| MY170941A (en) | Pyrimidine derivatives for the treatment of viral infections | |
| PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| MD4841B1 (ro) | Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică | |
| MX358099B (es) | Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. | |
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| MX347596B (es) | Derivados de purina para el tratamiento de infecciones viricas. | |
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX2013012053A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| WO2015086738A3 (en) | Hiv vaccine | |
| EA019080B9 (ru) | α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА | |
| WO2012100017A3 (en) | Antiretroviral cyclonucleoside compositions and methods and articles of manufacture therewith | |
| WO2011109104A3 (en) | Molecular clone of hiv-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |